[Electroencephalographic assessment of dosage and sleep-profile in a hypnotic Triazolothienodiazepine (author's transl)].
We 941, a Triazolodiazepine, has satisfying hypnotic properties. The optimum dosage lies nearly at 0.3 mg. In this dosage the sleep-begin is shortened, the number of nightly wakeness is decreased and the total sleep-time is extended, while the sleep-profile remains unchanged. A normal cycling can be taken as a sign of qualitative good sleep. The REM-percentage is diminished insignificantly and increases again under the continuated therapy. The percentage of deep sleep increases by 0.3 mg. The subjective presentations confirm the melioration of sleep. In higher dosages troubles occur as decrease of deep-sleep stage and deteriorations of feeling. Remarkable is the withdrawal effect after 1.0 mg with an initial and a dissociated REM. However, such strong disturbances couldn't be observed in the carried on therapy with 0.3 mg.
D000328:Adult; D001381:Azepines / Q000008:administration & dosage / Q000494:pharmacology*; D004562:Electrocardiography; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D010919:Placebos; D012890:Sleep / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology*; D014851:Wakefulness / Q000187:drug effects
D001381:Azepines; D006993:Hypnotics and Sedatives; D010919:Placebos; D014230:Triazoles; C020960:brotizolam
Elektroenzephalographische Dosis- und Schlafprofilbeurteilung eines Hypnotikums aus der Reihe der Triazolothienodiazepine.